Biomarin Pharmaceutical Inc (BMRN)

Net profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	426,859	322,291	256,589	205,455	167,645	147,021	99,991	71,615	141,561	83,912	54,070	39,347	-64,080	10,846	832,143	790,019	854,029	852,025	122,258	114,006
Revenue (ttm)	US$ in thousands	2,830,220	2,731,722	2,563,532	2,443,023	2,373,030	2,261,604	2,184,719	2,123,138	2,059,481	1,999,471	1,903,678	1,871,615	1,827,451	1,829,463	1,891,778	1,815,339	1,822,817	1,822,364	1,813,337	1,772,797
Net profit margin		15.08%	11.80%	10.01%	8.41%	7.06%	6.50%	4.58%	3.37%	6.87%	4.20%	2.84%	2.10%	-3.51%	0.59%	43.99%	43.52%	46.85%	46.75%	6.74%	6.43%

December 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $426,859K ÷ $2,830,220K
= 15.08%

The net profit margin of Biomarin Pharmaceutical Inc has shown fluctuations over the period from March 31, 2020, to December 31, 2024.

At the beginning of the period, in March 2020, the net profit margin was 6.43%, showing a moderate level of profitability. It increased slightly to 6.74% by June 2020. However, there was a significant jump in profitability in the latter half of 2020, with the net profit margin reaching 46.75% in September 2020 and remaining high at 46.85% in December 2020. This sharp increase could be due to various factors such as improved operational efficiency, cost control measures, or potentially one-time events impacting profitability positively.

The net profit margin experienced a slight decline in the first half of 2021, settling at 43.52% in March and 43.99% in June. The trend reversed in the second half of 2021, with a noticeable decline in profitability. The net profit margin dropped to 0.59% in September 2021 and turned negative at -3.51% in December 2021. Negative net profit margin indicates that the company incurred a loss during that period.

Subsequently, the company's profitability improved gradually in the following quarters. The net profit margin stood at 2.10% in March 2022 and increased to 2.84% in June 2022. There was a further uptick in profitability in the latter part of 2022 and throughout 2023, with the net profit margin reaching 7.06% by December 2023. The positive trend continued into 2024, with the net profit margin increasing to 15.08% by December 31, 2024, indicating a significant improvement in profitability compared to the beginning of the period.

Overall, the net profit margin of Biomarin Pharmaceutical Inc has displayed variability throughout the analyzed period, with some quarters exhibiting strong profitability while others showed fluctuations and occasional declines. It is essential for investors and stakeholders to monitor the company's profitability trend continuously to assess its financial performance and sustainability.